Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has received an average rating of "Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $24.13.
A number of equities research analysts recently issued reports on TEVA shares. UBS Group reduced their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Finally, Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th.
Get Our Latest Report on TEVA
Teva Pharmaceutical Industries Stock Performance
TEVA traded down $0.17 during trading on Monday, hitting $16.84. The stock had a trading volume of 9,521,157 shares, compared to its average volume of 12,209,508. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The company has a 50 day moving average price of $16.99 and a 200-day moving average price of $17.34. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $22.80. The firm has a market cap of $19.31 billion, a price-to-earnings ratio of -14.64, a P/E/G ratio of 0.87 and a beta of 0.60.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. Teva Pharmaceutical Industries's revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.48 earnings per share. As a group, research analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.
Insider Activity
In related news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.55% of the company's stock.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Oarsman Capital Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $29,000. Golden State Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $39,000. New Age Alpha Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth $43,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $44,000. Finally, Compagnie Lombard Odier SCmA acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at $54,000. Institutional investors and hedge funds own 54.05% of the company's stock.
Teva Pharmaceutical Industries Company Profile
(
Get Free ReportTeva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Recommended Stories
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
